Blood pressure reduction as part of the multifactorial approach to treatment of cardiovascular disease

G. Mancia, G. Grassi

Research output: Contribution to journalArticle

Abstract

Antihypertensive drug treatment has been unequivocally shown to exert favourable cardiovascular effects by reducing the incidence of (and delaying the occurrence of) major complications of hypertension, i.e. stroke, coronary atherosclerosis, congestive heart failure and renal insufficiency. Evidence has also been provided that the benefits of antihypertensive treatment (1) can be observed not only in diastolic or systo-diastolic hypertensive states but also in isolated systolic hypertensions and (2) are not related to a specific antihypertensive drug regimen but rather to the blood pressure lowering per se. The latter statement has been confirmed by the results of recently published clinical trials, demonstrating the ability of ACE inhibitors and calcium antagonists to exert cardioprotective properties similar to those induced by conventional antihypertensive drug treatment. Recent clinical trials have also shown that further advantages in patient protection can be achieved by lowering diastolic blood pressure values to well below 90 mmHg, particularly when high blood pressure is accompanied by diabetes and renal insufficiency.

Original languageEnglish
JournalEuropean Heart Journal, Supplement
Volume3
Issue numberB
DOIs
Publication statusPublished - 2001

Fingerprint

Antihypertensive Agents
Cardiovascular Diseases
Blood Pressure
Hypertension
Renal Insufficiency
Clinical Trials
Therapeutics
Angiotensin-Converting Enzyme Inhibitors
Coronary Artery Disease
Heart Failure
Stroke
Calcium
Incidence

Keywords

  • Antihypertensive treatment
  • Clinical trials
  • Management guidelines

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{3b80f1812b1947078cc920717f2052fc,
title = "Blood pressure reduction as part of the multifactorial approach to treatment of cardiovascular disease",
abstract = "Antihypertensive drug treatment has been unequivocally shown to exert favourable cardiovascular effects by reducing the incidence of (and delaying the occurrence of) major complications of hypertension, i.e. stroke, coronary atherosclerosis, congestive heart failure and renal insufficiency. Evidence has also been provided that the benefits of antihypertensive treatment (1) can be observed not only in diastolic or systo-diastolic hypertensive states but also in isolated systolic hypertensions and (2) are not related to a specific antihypertensive drug regimen but rather to the blood pressure lowering per se. The latter statement has been confirmed by the results of recently published clinical trials, demonstrating the ability of ACE inhibitors and calcium antagonists to exert cardioprotective properties similar to those induced by conventional antihypertensive drug treatment. Recent clinical trials have also shown that further advantages in patient protection can be achieved by lowering diastolic blood pressure values to well below 90 mmHg, particularly when high blood pressure is accompanied by diabetes and renal insufficiency.",
keywords = "Antihypertensive treatment, Clinical trials, Management guidelines",
author = "G. Mancia and G. Grassi",
year = "2001",
doi = "10.1016/S1520-765X(01)90055-0",
language = "English",
volume = "3",
journal = "European Heart Journal, Supplement",
issn = "1520-765X",
publisher = "Oxford University Press",
number = "B",

}

TY - JOUR

T1 - Blood pressure reduction as part of the multifactorial approach to treatment of cardiovascular disease

AU - Mancia, G.

AU - Grassi, G.

PY - 2001

Y1 - 2001

N2 - Antihypertensive drug treatment has been unequivocally shown to exert favourable cardiovascular effects by reducing the incidence of (and delaying the occurrence of) major complications of hypertension, i.e. stroke, coronary atherosclerosis, congestive heart failure and renal insufficiency. Evidence has also been provided that the benefits of antihypertensive treatment (1) can be observed not only in diastolic or systo-diastolic hypertensive states but also in isolated systolic hypertensions and (2) are not related to a specific antihypertensive drug regimen but rather to the blood pressure lowering per se. The latter statement has been confirmed by the results of recently published clinical trials, demonstrating the ability of ACE inhibitors and calcium antagonists to exert cardioprotective properties similar to those induced by conventional antihypertensive drug treatment. Recent clinical trials have also shown that further advantages in patient protection can be achieved by lowering diastolic blood pressure values to well below 90 mmHg, particularly when high blood pressure is accompanied by diabetes and renal insufficiency.

AB - Antihypertensive drug treatment has been unequivocally shown to exert favourable cardiovascular effects by reducing the incidence of (and delaying the occurrence of) major complications of hypertension, i.e. stroke, coronary atherosclerosis, congestive heart failure and renal insufficiency. Evidence has also been provided that the benefits of antihypertensive treatment (1) can be observed not only in diastolic or systo-diastolic hypertensive states but also in isolated systolic hypertensions and (2) are not related to a specific antihypertensive drug regimen but rather to the blood pressure lowering per se. The latter statement has been confirmed by the results of recently published clinical trials, demonstrating the ability of ACE inhibitors and calcium antagonists to exert cardioprotective properties similar to those induced by conventional antihypertensive drug treatment. Recent clinical trials have also shown that further advantages in patient protection can be achieved by lowering diastolic blood pressure values to well below 90 mmHg, particularly when high blood pressure is accompanied by diabetes and renal insufficiency.

KW - Antihypertensive treatment

KW - Clinical trials

KW - Management guidelines

UR - http://www.scopus.com/inward/record.url?scp=0034932466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034932466&partnerID=8YFLogxK

U2 - 10.1016/S1520-765X(01)90055-0

DO - 10.1016/S1520-765X(01)90055-0

M3 - Article

VL - 3

JO - European Heart Journal, Supplement

JF - European Heart Journal, Supplement

SN - 1520-765X

IS - B

ER -